Answers are grounded in this paper and cite their sources.
(See the Major Article by Phu et al on pages e465–e470 in Volume 71, Number 9, November 1 2020 issue) In “Concomitant bacteremia in adults with severe falciparum malaria” in this issue of Clinical Infectious Diseases, 9 of 845 Southeast Asian adults with severe malaria (1%) had bacteremia upon admission, but 4 of those 9 patients (44%) died compared with 108 of 836 (13%) nonbacteremic patients [1]. The grim prognosis for adults with severe malaria complicated by bacteremia necessitates immediate antibacterial as well as antimalarial treatment, but unlike Plasmodia, which take minutes to identify, bacteria take days to grow in culture. Whether or not to institute antibacterial therapy has to be based on pre-existing recommendations rather than on data for the individual patient. Empiric antibacterial agents are recommended for severe malaria in children in endemic regions [2, 3], for whom in Africa the incidence of bacteremia is more than 6% [4]. For adults, where, in Southeast Asia, the incidence of bacteremia is 1%, Phu et al [1] propose that “20% parasitemia” reasonably identifies those patients with severe malaria likely to be bacteremic, thus needing empiric antibacterial treatment at admission. Their reasoning can be seen from a table (Table 1) constructed from the publication: Survival of Different Patient Populations Survival of Different Patient Populations The 4 patients with both bacteremia and more than 20% parasitemia had a 75% death rate, far higher than the death rate for the other 3 populations. Conversely, if all 76 patients with more than 20% parasitemia were to receive empirical antibacterial therapy, those 3 lives might be saved. The authors do not propose administering antibacterials to the 769 patients with less than 20% parasitemia, by implication because, for that patient population, only 5 of 769 patients were bacteremic of whom 1 died. The recommendations of Phu et al to administer antibacterials to adults with more than 20% parasitemia seems a judicious enlargement of the World Health Organization (WHO) guidelines for children to include a subset of adults. The authors remark that prior publications suggesting empirical antibacterial therapy for all adults with severe malaria were likely to have been based on data from patients with bacterial septicemia complicated by nonsevere malaria, rather than severe malaria complicated by bacteremia, 2 conditions that can present similarly. The analysis of Phu et al is based on data from 1991–2003 in which severe malaria was treated with intramuscular quinine, artemether, or artesunate. Present WHO recommendations [3] are as follows: “Treat adults and children with severe malaria (including infants, pregnant women in all trimesters, and lactating women) with intravenous (IV) or intramuscular artesunate for at least 24 hrs. Once a patient has received at least 24 hrs of parenteral therapy and can tolerate oral therapy, complete treatment with 3 days of an ACT [artemisinin-based combination therapy] …. Children weighing <20 kg should receive a higher dose of artesunate (3 mg/kg per dose) than larger children and adults (2.4 mg/kg per dose) to ensure equivalent exposure to the drug.” On 26 May 2020, IV artesunate (“Artesunate for Injection”) was approved by the US Food and Drug Administration (FDA) for the treatment of severe malaria [5]. The indication is “initial treatment of severe malaria in adult and pediatric patients “and the recommended regimen is “2.4 mg/kg administered intravenously at 0 hours, 12 hours, and 24 hours, and thereafter administered once daily until the patient is able to tolerate oral antimalarial therapy.” The US label reflects discussion of several issues suggested by the WHO recommendations, as follows: Population to be treated: as per WHO, all human populations. Disease to be treated: as per WHO, all severe malaria irrespective of Plasmodium species. Dose level: 2.4 mg/kg per dose. The WHO recommendation to increase the dose level in children weighing less than 20 kg, based on pharmacokinetic analyses which indicated lower exposure in that weight band, was not adopted. A re-analysis apparently performed by the FDA indicated higher (not lower) exposure in persons weighing less than 20 kg compared with those weighing more than 20 kg [5]. Also, pharmacodynamic data do not suggest that children have an efficacy disadvantage. When Southeast Asians were treated with 2.4 mg/kg per dose, children had a higher survival rate (95%) than adults (84%) [6]. 4. Number of doses: at least 3 doses over 24 hours, then daily until oral antimalarials can be administered. Neither the WHO nor US recommendations specify the maximum number of doses. Clinicians may benefit from the experience using IV artesunate in the United States, for which median time to starting oral antimalarials was 4 days [7]. 5. Route of administration: intravenous The reasons to limit administration to the IV route may be that drug was given by that route in the pivotal trial (“Seaquamat” [6]) and in 1 of the 2 supporting trials [7, 8], and that intramuscular administration would not be needed for treatment in the United States. 6. Efficacy: in the controlled pivotal trial ([6] designated “Trial #1” in the label) in which IV artesunate was compared with IV quinine, the death rates were 13% versus 21%, respectively, for Southeast Asians [5]. In the controlled supporting trial in which parenteral (IV or intramuscular) artesunate was compared with parenteral quinine in African children ([8]; designated “trial #2” in the label), 8.5% of artesunate patients versus 10.9% of quinine patients died [8]. This 22–38% survival advantage of artesunate indicates that (IV) artesunate is superior to the classic standard of care, (IV) quinine, in developing nations and has led to the adoption of IV artesunate for severe malaria worldwide. However, treatment of severe malaria reflects the combined activity of 2 interventions: in-hospital support plus specific antimalarial therapy. Since in-hospital support may differ between the developing and the developed world, the efficacy of IV artesunate in US and French studies, although uncontrolled, may best predict outcomes in future US and developed-world use. In the uncontrolled US study used to support the label ([7]; designated “Trial #3” in the label), 102 patients aged 1 to 72 years with severe or complicated malaria received at least 4 doses of intravenous artesunate (2.4 mg/kg per dose) in 2007–2010 via a compassionate-use IND (Investigational New Drug). There were 7 deaths (6.9% [7]). For 2016, in the United States, the last year for which the Centers for Disease Control and Prevention has published data, there were 29 severe malaria cases treated with IV artesunate, of whom 1 died (3.4% [9]). In a recently published review of severe malaria seen in France from 2011 to 2017, 22 of 1084 IV artesunate patients (2.9%) died [10]. In the US study, the median time to discharge from the intensive care unit was 4 days, even for patients who presented with severe liver disease or cerebral malaria. For the 87 patients infected with P. falciparum who were evaluable, the median time to negative parasitemia was 43 hours [7]. 7. Adverse reactions: the WHO guidelines mention hypersensitivity (1/3000), gastrointestinal reactions, cough, rash, arthralgia, dizziness, delayed hemolysis, and neutropenia [3]. The US label contains “Warnings” for hypersensitivity and post-treatment hemolysis, and lists acute renal failure requiring dialysis, hemoglobinuria, and jaundice as the most common adverse reactions occurring in 2% or more of artesunate patients and to a greater extent than in the comparator quinine group [5]. The approval of Good-Manufacturing-Practice intravenous artesunate for severe malaria via FDA’s rigorous review process gives confidence that this life-saving treatment can be safely and effectively used for what is otherwise a mortal disease. Disclaimer: No one at Fast-Track or AMIVAS has seen the manuscript. All the information in the manuscript derives from the open literature. Potential conflicts of interest. The author is an employee of Fast-Track Drugs and Biologics, which has a contractual relationship with AMIVAS, the NDA sponsor of Artesunate for Injection. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
No takes yet. Share an insight, caveat, or question.
Jonathan D. Berman (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: